Tags : Nosopharm

Nosopharm Signs an Agreement with Evotec to Accelerate the Development

Shots: Nosopharm and Evotec collaborated to advance Nosopharm’s NOSO-502 to clinical stage and to develop second-generation Odilorhabdin (ODLs) for hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), under the name NOSO-2G The collaboration initially focuses on Chemistry, Manufacturing and Control (CMC) and Clinical Trial Application (CTA)-enabling and filing activities regarding NOSO-502 for the onset of P-I study […]Read More